Baxter spinoff Baxalta officially independent; Cosmo Pharma aims for 163M francs in Cassiopea offering;

@FiercePharma: UPDATED: Bayer, J&J touting Xarelto trial data to counteract Eliquis surge. More | Follow @FiercePharma

@EricPFierce: Join us July 8 for a Twiiter chat on #sustainedrelease with BASF expert Thorsten Cech. Details are here. | Follow @EricPFierce

@CarlyHFierce: Not gonna lie, I purposely use the phrase "the Illinois pharma" every time I write about an Illinois pharma. | Follow @CarlyHFierce

> Baxalta is now officially a standalone company after its $6 billion spinoff from Baxter International ($BAX), with a product line specializing in hemophilia. Report

> Cosmo Pharmaceuticals, in an attempt to raise 163 million Swiss francs, is cutting its stake in the skin and hair treatment company Cassiopea via a public stock offering. Report

> Teva Pharmaceutical ($TEVA) and Philips ($PHG) are together investing up to 100 million shekels ($26.5 million) in medical device and health technology startups in Israel. Report

> Indivior announced a new trial date in a Suboxone patent fight against Watson Laboratories, now Allergan ($AGN), and Par Pharmaceutical. Report

> Johnson & Johnson ($JNJ) cut its carbon emissions in 2014, but it's close to missing its target for water consumption in 2015. Report

> A hotel workers' union started an online campaign to chase pharma funding out of continuing medical education. Report

Medical Device News

@FierceMedDev: UPDATED: American Heart Association guidelines encourage use of stent retrievers to treat stroke. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Microchips Biotech partners with Teva on wireless drug delivery, announces new CEO, raises $18M in financing. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Pay friends to quit smoking with Pfizer's new digital tool. FiercePharmaMarketing article | Follow @EmilyWFierce

> Feds sentence woman to 97 months in prison for fraudulently billing Medicare for wheelchairs. News

> ViewRay gets $50M in debt to back MRI-guided radiation therapy after IPO withdrawal. Story

Biotech News

@FierceBiotech: FierceBiotech Radio on the cost of CAR-T, the future of Zoetis, and gentrification in Kendall Square. Listen | Follow @FierceBiotech

@JohnCFierce: Trending: Is Celgene killing the traditional biotech partnering formula? Editor's corner | Follow @JohnCFierce

@DamianFierce: Join us as we search for the Amar'e Stoudemire of immuno-oncology. FierceBiotech Radio | Follow @DamianFierce

> Purdue pulls out of FDA panel on abuse-deterrent OxyContin just days before meeting. Report

> Whittled down to biotech size, AstraZeneca's antibiotics crew starts over as Entasis. News

Biotech Research News

> Researchers highlight a nuanced approach to flagging early Alzheimer's. Article

> Antibody 'cocktail' looks promising against deadly Marburg virus. News

> Salk investigators develop a new autophagy combo drug to starve tumors. More

> Dual cancer role for Daple attracts research team at UC San Diego. Article

> UCL team sees promise in mouse study of pancreatic tumor-targeting compound. Story

Diagnostics News

> Cinven snatches up Synlab for $1.96B to beef up in diagnostics. More

> Luxembourg's Eurofins rides JV diagnostics wave with Emory University deal. Editor's corner

> NIH provides Great Basin Scientific and BYU $5M+ to develop rapid test for CRE. Story

> Illumina unveils plans for new European HQ and science center. Item

> Qiagen launches Germany-based JV aimed at companion Dx. Article

Pharma Marketing News

> Feds demand $3.4B in damages, fines in Novartis kickback case. Story

> Latest Sunshine Act bombshell: $6.5B in doc-and-hospital payments last year. More

> House bill would force FDA to ease up on social media. Article

> Pay friends to quit smoking with Pfizer's new digital tool. Story

> Bayer, J&J touting Xarelto trial data to counteract Eliquis surge. Report

And Finally... Oklahoma said it would quickly resume executions after the Supreme Court said it was legal to use a controversial drug in its lethal injections. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.